In summary, our results demonstrate that low-dose PTX prevents EMT transition and ameliorates pulmonary fibrosis by upregulating miR-140 expression to further suppress the TGF-β1/Smad3 pathway, which highlighted a new way for pulmonary fibrosis therapy. The gene discussed is TGFB1; the disease is pulmonary fibrosis.